ZYPREXA RELPREVV Drug Patent Profile

When do Zyprexa Relprevv patents expire, and when can generic versions of Zyprexa Relprevv launch?

Zyprexa Relprevv is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in ZYPREXA RELPREVV is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.

Summary for ZYPREXA RELPREVV

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	33
Patent Applications:	66
Drug Prices:	Drug price information for ZYPREXA RELPREVV
DailyMed Link:	ZYPREXA RELPREVV at DailyMed

See drug prices for ZYPREXA RELPREVV

US Patents and Regulatory Information for ZYPREXA RELPREVV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-001	Dec 11, 2009		RX	Yes	No
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-002	Dec 11, 2009		RX	Yes	No
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-003	Dec 11, 2009		RX	Yes	Yes

Expired US Patents for ZYPREXA RELPREVV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-003	Dec 11, 2009	6,169,084
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-001	Dec 11, 2009	6,169,084
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-002	Dec 11, 2009	6,169,084

International Patents for ZYPREXA RELPREVV

See the table below for patents covering ZYPREXA RELPREVV around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	359793
Germany	19675046
Taiwan	577890
Finland	911986

Supplementary Protection Certificates for ZYPREXA RELPREVV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	9/1997	Austria		PRODUCT NAME: OLANZAPIN ODER EIN SAEUREADDITIONSSALZ HIEVON; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
0454436	CA 2001 00042	Denmark
0454436	SPC/GB96/058	United Kingdom		PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
0454436	97C0012	Belgium		PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927

Market Dynamics and Financial Trajectory for ZYPREXA RELPREVV (Olanzapine pamoate)

Last updated: January 25, 2026

Summary

ZYPREXA RELPREVV (olanzapine pamoate) is an atypical antipsychotic formulated for long-acting injectable (LAI) administration, primarily used in the treatment of schizophrenia. Since its FDA approval in 2014, its market trajectory has been influenced by factors such as evolving treatment guidelines, payer policies, competitive landscape, and patient adherence challenges. This report assesses current market dynamics, projections of revenue, key drivers, obstacles, and future growth potential, providing a comprehensive financial outlook aligned with industry trends.

---

What Is ZYPREXA RELPREVV and How Does It Differ?

Attribute	Details
Generic Name	Olanzapine pamoate
Brand Name	ZYPREXA RELPREVV
Formulation	Long-acting injectable (LAI)
Indication	Schizophrenia (FDA approval in 2014)
Mechanism	D2/5-HT2A receptor antagonist
Administration	Monthly intramuscular injections

ZYPREXA RELPREVV is distinguished by its extended-release profile, reducing daily pill burden and aiming to improve patient adherence compared to oral formulations. It shares active ingredient similarities with oral ZYPREXA (olanzapine), but its delivery mode offers distinct market advantages.

---

Market Size and Demand Drivers

Global Market Valuation (2023)

Parameter	Estimate (USD)	Notes
Global Schizophrenia Market	$7.5 billion	Expected CAGR (2023-2028): 3.2%[^1]
LAI Antipsychotics Market	$3.2 billion	Approximate share for ZYPREXA RELPREVV: 15–20%

United States Market Share

Year	Sales (USD)	Key Drivers
2014	$20 million	Launch phase
2018	$125 million	Expanded prescriber base, insurance coverage
2022	$180 million	Increased awareness, inclusion in guidelines

Demand Influences

• Patient Adherence: LAI formulations like ZYPREXA RELPREVV reduce non-compliance, a major factor for treatment success.
• Guideline Endorsement: Inclusion in schizophrenia management guidelines by AASNP (American Association of Psychiatric Pharmacists) and APA (American Psychiatric Association) boosts prescribing.
• Reimbursement Policies: Insurance coverage significantly affects access; recent tightening of prior authorization can impede growth.
• Generics and Competition: Oral olanzapine remains generic and less costly, impacting LAI's market penetration.

---

Competitive Landscape

Major Competitors	Drug Name	Formulation	Market Position	Key Differentiator
Janssen	Risperdal Consta	LAI	Major LAI	Long-standing market presence
Lundbeck	Abilify Maintena	LAI	Growing	Broad indications
Alkermes	Aristada	LAI	Niche	Extended dosing interval variants
Otsuka	INVEGA Sustenna	LAI	Leading	Well-established brand

ZYPREXA RELPREVV faces competition primarily from risperidone and aripiprazole-based LAIs. Its distinct value proposition lies in its rapid onset and tolerability profile.

---

Regulatory and Reimbursement Policies

Aspect	Details
FDA Approval Date	January 2014[^2]
Coverage Trends	Insurance coverage varies; notable for requiring prior authorization in several cases
Reimbursement Rates	Reimbursement can range from 70-90%, depending on payer and negotiated contracts
Pricing	Approximate list price: $1,300–$1,500 per injection (monthly dose)
Impact	Reimbursement and coverage are critical for expanding access and sales growth

---

Financial Trajectory and Forecasts

Period	Projected Sales (USD million)	Assumptions & Drivers
2023	$200	Continued adoption, insurance coverage
2024	$250	Increased prescriber awareness, expanded guidelines
2025	$280	Market penetration into Medicaid populations, new patient segments
2026+	$300+	Competitive stabilization, potential label expansions

Key Revenue Drivers

• Patient Enrollment Growth: Estimated 10–15% annual growth driven by new initiations.
• Market Penetration: Incremental increases in hospital and outpatient settings.
• Pricing Strategies: Premium pricing justified by improved adherence and reduced hospitalization costs.
• Market Expansion: Potential indications and formulations (e.g., extended dosing intervals).

Economic Impact Analysis

Studies suggest LAIs like ZYPREXA RELPREVV reduce hospitalization rates by up to 25% (compared to oral), translating into significant healthcare cost savings that support its reimbursement value and market expansion.

---

Market Challenges and Barriers

Challenge	Impact	Mitigation Strategies
High Cost	Limits access, especially in Medicaid populations	Pricing negotiations, value-based contracts
Reimbursement Hurdles	Delays in initiation	Payer engagement, educational initiatives
Competition from Generics	Oral olanzapine is cheaper; impacts LAI sales	Highlight adherence benefits and reduced relapse costs
Limited Indications	Restricted to schizophrenia	Research into bipolar disorder and other indications

---

Future Opportunities and Growth Potential

Opportunity Area	Details	Projected Impact
Label Expansion	Potential approval for bipolar disorder	Broadened patient base
Dosing Innovations	Longer dosing intervals (quarterly, biannual) under development	Market differentiation and patient convenience
Payer Incentives	Value-based agreements linked to outcomes	Improved coverage, increased adoption
New Formulations	Combination therapies or orally disintegrating versions	Enhanced patient adherence

---

Comparison of Key Long-Acting Antipsychotics

Parameter	ZYPREXA RELPREVV	Risperdal Consta	Abilify Maintena	Aristada	Invega Sustenna
FDA Approval Year	2014	2003	2015	2015	2006
Dosing Interval	Monthly	Every 2 weeks	Monthly	Monthly / 6-8 weeks	Monthly
Cost per Dose (USD)	~$1,400	~$1,100	~$1,500	~$2,000	~$1,400
Typical Use Cases	Schizophrenia	Schizophrenia	Schizophrenia, bipolar	Schizophrenia	Schizophrenia

---

FAQs

Q1: What are the primary factors influencing ZYPREXA RELPREVV's market growth?
A1: Prescriber acceptance, insurance coverage, competitive dynamics, patient adherence benefits, and reimbursement policies.

Q2: How does ZYPREXA RELPREVV compare cost-wise to oral olanzapine?
A2: The monthly injection costs approximately $1,400–$1,500, while generic oral olanzapine is roughly $0.50–$1 per tablet, totaling significantly less but with lower adherence benefits.

Q3: What are the main barriers to wider adoption of ZYPREXA RELPREVV?
A3: High upfront cost, reimbursement hurdles, limited formulary placement, and competition from generics.

Q4: Are there upcoming version or label expansions for ZYPREXA RELPREVV?
A4: Currently under investigation for bipolar disorder and longer-acting formulations, with potential regulatory submissions in the next few years.

Q5: What role do healthcare policies play in shaping ZYPREXA RELPREVV’s market?
A5: Policies favoring adherence and reducing healthcare costs support LAI adoption but also impose reimbursement and approval constraints.

---

Key Takeaways

• ZYPREXA RELPREVV has solidified its position in the schizophrenia LAI market since 2014, with revenues projected to grow steadily from ~$200 million in 2023 to $280 million by 2025.
• Key drivers include improved adherence rates, inclusion in treatment guidelines, and ongoing efforts to expand indications and formulations.
• Competition remains fierce with established brands like Risperdal Consta and Abilify Maintena, along with the attractive lower-cost oral olanzapine.
• Reimbursement challenges and high drug prices serve as significant barriers; strategic payer negotiations and value-based contracts are essential.
• Future growth hinges on innovation (longer dosing intervals), label expansion, and broader payer acceptance, positioning ZYPREXA RELPREVV as a critical component in schizophrenia treatment paradigms.

---

References

[^1]: GlobalData Reports on Schizophrenia Market, 2023
[^2]: US FDA Approval Announcement, January 2014